BriaVax Breast Cancer Vaccine Development Going According to Plan, Company Says

BriaVax Breast Cancer Vaccine Development Going According to Plan, Company Says
BriaCell Therapeutics’ Phase 1/2a study of the breast cancer vaccine BriaVax is proceeding according to plan, the company recently announced. Six patients with advanced breast cancer have received the therapeutic vaccine, which intends to trigger an immune response against the cancer. The study (NCT03066947), in which researchers treated and evaluated the first three patients in

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *